Stock Track | Belite Bio Soars 5.43% as Maxim Group Boosts Price Target to $140

Stock Track

Nov 12

Belite Bio, Inc. (NASDAQ: BLTE) saw its stock surge 5.43% in pre-market trading on Wednesday, following a significant price target upgrade from Maxim Group. The healthcare company's shares reacted positively to the analysts' increased confidence in its future prospects.

Maxim Group, a well-known financial services firm, raised its price target for Belite Bio to $140 from the previous $110. This represents a substantial 27% increase in the projected value of the company's stock. The upgrade suggests that Maxim Group analysts have become more optimistic about Belite Bio's growth potential and market position.

While specific reasons for the price target increase were not provided in the available news, such upgrades are typically based on factors like improved financial performance, promising drug development progress, or positive industry trends. Investors appear to be responding favorably to this vote of confidence from Maxim Group, as reflected in the pre-market stock movement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1140977509"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140977509\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140977509?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140977509","market":"nz","top_or_hot":-1,"title":"Stock Track | Belite Bio Soars 5.43% as Maxim Group Boosts Price Target to $140","media":"Stock Track","content":"<p>Belite Bio, Inc. (NASDAQ: BLTE) saw its stock surge 5.43% in pre-market trading on Wednesday, following a significant price target upgrade from Maxim Group. The healthcare company's shares reacted positively to the analysts' increased confidence in its future prospects.</p>\n\n<p>Maxim Group, a well-known financial services firm, raised its price target for Belite Bio to $140 from the previous $110. This represents a substantial 27% increase in the projected value of the company's stock. The upgrade suggests that Maxim Group analysts have become more optimistic about Belite Bio's growth potential and market position.</p>\n\n<p>While specific reasons for the price target increase were not provided in the available news, such upgrades are typically based on factors like improved financial performance, promising drug development progress, or positive industry trends. Investors appear to be responding favorably to this vote of confidence from Maxim Group, as reflected in the pre-market stock movement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Belite Bio Soars 5.43% as Maxim Group Boosts Price Target to $140</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Belite Bio Soars 5.43% as Maxim Group Boosts Price Target to $140\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Belite Bio, Inc. (NASDAQ: BLTE) saw its stock surge 5.43% in pre-market trading on Wednesday, following a significant price target upgrade from Maxim Group. The healthcare company's shares reacted positively to the analysts' increased confidence in its future prospects.</p>\n\n<p>Maxim Group, a well-known financial services firm, raised its price target for Belite Bio to $140 from the previous $110. This represents a substantial 27% increase in the projected value of the company's stock. The upgrade suggests that Maxim Group analysts have become more optimistic about Belite Bio's growth potential and market position.</p>\n\n<p>While specific reasons for the price target increase were not provided in the available news, such upgrades are typically based on factors like improved financial performance, promising drug development progress, or positive industry trends. Investors appear to be responding favorably to this vote of confidence from Maxim Group, as reflected in the pre-market stock movement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLTE","symbol_name":"Belite Bio, Inc.","start_time":0,"source_url":"","article_id":"1140977509","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140977509","pubTimestamp":1762958079,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Belite Bio, Inc. (NASDAQ: BLTE) saw its stock surge 5.43% in pre-market trading on Wednesday, following a significant price target upgrade from Maxim Group. The healthcare company's shares reacted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLTE":"Belite Bio, Inc."},"translate_title":"个股追踪|美信集团上调目标价至140美元贝利特生物大涨5.43%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLTE":1},"content_text":"Belite Bio, Inc. (NASDAQ: BLTE) saw its stock surge 5.43% in pre-market trading on Wednesday, following a significant price target upgrade from Maxim Group. The healthcare company's shares reacted positively to the analysts' increased confidence in its future prospects.\nMaxim Group, a well-known financial services firm, raised its price target for Belite Bio to $140 from the previous $110. This represents a substantial 27% increase in the projected value of the company's stock. The upgrade suggests that Maxim Group analysts have become more optimistic about Belite Bio's growth potential and market position.\nWhile specific reasons for the price target increase were not provided in the available news, such upgrades are typically based on factors like improved financial performance, promising drug development progress, or positive industry trends. Investors appear to be responding favorably to this vote of confidence from Maxim Group, as reflected in the pre-market stock movement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}